breast

Timothy Yap MD PhD MBBS selective PARP inhibitor promise in breast, ovarian, pancreatic, prostate tumors.

Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan) Sarah Maxwell and Peter Goodwin report from: American Society of Clinical Oncology

Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan) Commenting Expert: Michael Untch, HELIOS Klinikum, Berlin In this edition Peter Goo

Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan) Commenting Expert: Emiel Rutgers, Netherlands Cancer Institute, Amsterdam Angel Rod

Scientific Editors: George Canellos, Pat Price, Gordon McVie, Gianni Bonadonna In this edition: Bevacizumab and Survival in Metastatic Breast Cancer Source: N Engl J Med 357:26 George Canellos, Dana-F

Cora Sternberg REFERENCE: Abstract 4010, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 CORA STERNBERG, San Camillo and Forlanini Hospital, Rome Satraplatin could pro

Zulfiqar Bhutta Reference: The Lancet, Maternal and Child Undernutrition Special Series With one child in three killed by it, childhood and maternal undernutrition are discussed in a special series of

Jack Cuzick JACK CUZICK, Wolfson Institute of Preventive Medicine, London New data from the ATAC trial, which is testing anastrozole and tamoxifen in early breast cancer, have demonstrated the continu

Jose Baselga JOSE BASELGA, Vall d’Hebron Hospital, Barcelona RAD001, a drug targeted at the mTor pathway, has been combined with letrozole in a randomised phase II trial in breast cancer. The in

Jean-Yves Douillard Gordon McVie REFERENCE: Abstracts: 6507 & 2LB, ECCO 14, The European Cancer Conference, Barcelona, 23 Р27 September 2007 JEAN-YVES DOUILLARD, Centre Ren̩ Gauducheau, N

Nicholas James Gordon McVie REFERENCE: Abstract: 3LB (Presidential Session), ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 NICHOLAS JAMES, Birmingham University COMM

Jose Baselga Gordon McVie REFERENCE: ABSTRACT 2030, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 JOSE BASELGA, Vall d’Hebron University Hospital, Barcelona CO

Pierre Guillou David Jayne REFERENCE: J Clin Oncol 25:3061-3068 PIERRE GUILLOU, St James’ Hospital, Leeds COMMENT: DAVID JAYNE, St James’ Hospital, Leeds Laparoscopic-assisted resection fo

Rachel Johnson Terry Mamounas William Gradishar Withhold Trastuzumab in Low-Risk Patients with HER-2 Positive Breast Cancer? REFERENCE: Abstract: 2090 RACHEL JOHNSON, Christie Hospital, Manchester Som

IAN SMITH, Royal Marsden Hospital, London REFERENCE: Lancet 369:29 Confirmation of the life-extending benefits of trastuzumab adjuvant therapy for early breast cancer has been published recently in th

Dennis Slamon George Peoples James Holland Massimo Christofanilli Trastuzumab: Mature Results in Early Breast Cancer Show Superiority REFERENCE: San Antonio Breast Cancer Symposium 2006, Abstract: 52

Clifford Hudis Mark Einstein Tony Greco James Berenson Edward Ambinder Breast Cancer: HER2 Still a Useful Target After Trastuzumab Resistance REFERENCE: Chemotherapy Foundation Symposium XXIV 8-11 Nov

David Cameron Martine Piccart Eric Van Cutsem Jim Cassidy Volker Heinemann Lapatinib Better for Patients with HER2+ Refractory Breast Cancer Pre-treated with Chemotherapy and Trastuzumab REFERENCE: ES

Gordon McVie Martine Piccart Bella Kaufman Jean-Yves Douillard ESMO Congress Reviewed GORDON MCVIE, European Institute of Oncology, Milan In Istanbul, Gordon McVie gave his opinion about the achieveme

George Canellos Sandra Strauss Nancy Baxter KIT Mutations in Acute Myeloid Leukemia Confer Higher Relapse Risk Liver Metastasis Resection Not Curative for Colorectal Cancer Patients With Node Negative

Robert Ozols William See Ruth Lupu Improving on Standard Treatment in Ovarian Cancer: Have We Hit a Wall? REFERENCE: Abstract 5002, 2006 ASCO Annual Meeting; N Engl J Med 2006, 354:34-43 ROBERT OZOLS,

Joan Houghton Elizabeth Barrett-Connor Fran Balkwill Carl Christophe Schimanski Adjuvant Anastrozole for Patients With Breast Cancer: Long-Term Safety Results From the ATAC Study REFERENCE: Lancet Onc

Julie Gralow Charles Geyer Judith Bliss Robert Coleman Julie Gralow, from the Fred Hutchinson Cancer Research Center in Seattle, joins Derek Thorne to talk about the latest news from the ASCO annual m

Reporting from: – San Antonio Breast Cancer Symposium, December 8-11, 2004 – European Society for Medical Oncology Congress, October 29-November 10, 2004, Vienna In this edition: Raimund J